Research programme: transient receptor potential channel therapeutics - PharmEste

Drug Profile

Research programme: transient receptor potential channel therapeutics - PharmEste

Alternative Names: PHE 575; TRPA1 antagonists; TRPV1 antagonists

Latest Information Update: 04 Nov 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator PharmEste
  • Class
  • Mechanism of Action TRPA1 protein inhibitors; TRPV1 receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • Available For Licensing Yes

Highest Development Phases

  • No development reported Neuropathic pain; Overactive bladder; Respiratory tract disorders

Most Recent Events

  • 04 Nov 2017 No recent reports of development identified for preclinical development in Neuropathic-pain in Italy
  • 04 Nov 2017 No recent reports of development identified for research development in Respiratory-tract-disorders in Italy
  • 24 May 2011 Research programme: transient receptor potential channel therapeutics - PharmEste is available for licensing as of 24 May 2011. http://www.pharmeste.com
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top